Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ: LGND · USD

$318

+6.08 (+1.9%)· Recorded snapshot

Market cap	6.3B
Revenue (ttm)	290.5M
Net income (ttm)	197.2M
EPS (ttm)	$9.19
Shares out	19.9M
P/E (trailing)	34.6x
P/E (forward)	45.5x
Volume	222,623
Beta	1.01

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 290.5M
Net income (ttm): 197.2M
EPS (ttm): $9.19
P/E (trailing): 34.6x
P/E (forward): 45.5x
Market cap: 6.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E45.5

P25 n/aP50 n/aP75 n/a

Trailing P/E34.6

P25 n/aP50 n/aP75 n/a

ROE22

P25 n/aP50 n/aP75 n/a

ROIC11.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All LGND indicators

Market & fundamental data

Available fields

276

Groups with data

Currency

USD

Showing 276 of 276 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000886163
Company name	Ligand Pharmaceuticals Incorporated
Country	United States
Country code	US
CUSIP number	53220K504
Earnings date	2026-10-29
Earnings time	bmo
Employees	47
Employees change	-21
Employees growth	-30.88%
Enterprise value	$6.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1987
In index	RUSSELL2000
Industry	Biotechnology
IPO date	1992-11-18
Is primary listing	Yes
Is SPAC	No
ISIN number	US53220K5048
Last 10-K release date	2026-02-27
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2010-11-19
Last stock split type	Reverse
Market cap	$6.3B
Market cap category	Mid-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$317.81
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	LGND
U.S. state	Florida
Website	https://www.ligand.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	34.89x
Average P/E ratio (10Y)	65.33x
Average P/E ratio (3Y)	37.27x
Average P/E ratio (5Y)	42.36x
Earnings yield	2.89%
EV/Earnings	30.29x
EV/EBIT	59.67x
EV/EBITDA	44.91x
EV/FCF	45.45x
EV/Sales	20.56x
FCF / EV yield	2.2%
FCF yield	2.12%
Forward EV/Sales	17.8x
Forward P/E	45.5x
Forward P/S	18.47x
Graham number	100.23059
Graham upside	-67.77%
Lynch fair value	$229.82
Lynch upside	-26.1%
P/(FCF - SBC) ratio	79.31x
P/(OCF - SBC) ratio	79.03x
P/B ratio	6.42x
P/E ratio	34.57x
P/FCF ratio	47.17x
P/OCF ratio	47.07x
P/S ratio	21.34x
PEG ratio	1.84x
Price / tangible book value	9.44x
Price/EBITDA ratio	46.61x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	34.45%
EBITDA margin	45.78%
Effective tax rate	17.12%
FCF margin	45.24%
Gross margin	81.2%
Operating margin	34.45%
Pretax margin	81.9%
Profit margin	67.88%
Profit per employee	$4.2M
Profitable quarters	1
Profitable years	1
Revenue per employee	$6.2M
ROA	3.99%
ROA (5Y)	1.62%
ROCE	4.68%
ROE	21.96%
ROE (5Y)	6.1%
ROIC	11.76%
ROIC (5Y)	1.82%
SBC / revenue	18.33%
Tax / revenue	14.02%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	825%
EPS growth 10Y	-0.59%
EPS growth 3Y	80.56%
EPS growth 5Y	26.05%
EPS growth quarters	5
EPS growth years	1
FCF growth	145.13%
FCF growth (Q)	53.94%
FCF growth (QoQ)	-50.49%
FCF growth 3Y	10%
FCF growth 5Y	29.6%
Gross profit growth	118.87%
Gross profit growth (Q)	20.07%
Gross profit growth 3Y	30.22%
Gross profit growth 5Y	13.32%
Net income growth (Q)	900.78%
Net income growth 3Y	93.65%
Net income growth 5Y	32.72%
Net income growth quarters	5
Net income growth years	1
OCF growth	137.94%
OCF growth (Q)	52.02%
OCF growth (QoQ)	-50.67%
OCF growth 10Y	10.72%
OCF growth 3Y	6.9%
OCF growth 5Y	24.29%
Operating income growth (Q)	-11.62%
Operating income growth 3Y	181.99%
Operating income growth 5Y	23.46%
Revenue growth	54.89%
Revenue growth (Q)	33.73%
Revenue growth (QoQ)	23.14%
Revenue growth 10Y	12.68%
Revenue growth 3Y	17.32%
Revenue growth 5Y	2.91%
Revenue growth quarters	9
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-278,000
Depreciation and amortization	$32.9M
EBIT	$100.1M
EBITDA	$133M
EPS	$9.19
FCF per share	$6.59
Financing cash flow	$950.3M
Free cash flow	$131.4M
Free cash flow minus SBC	$78.2M
Gross profit	$235.9M
Income taxes	$40.7M
Investing cash flow	$-144.8M
Net borrowing	$850.9M
Net cash flow	$939M
Net income	$197.2M
Operating cash flow minus SBC	$78.4M
Operating income	$100.1M
Revenue	$290.5M
Stock-based compensation	$53.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.31
Book value per share	$48.57
Debt / EBITDA	8.46
Debt / equity	1.17
Debt / FCF	8.61
Goodwill	$101.5M
Interest coverage	16.17
Long-term assets	$728.8M
Long-term liabilities	$1.2B
Net cash (debt)	$226.3M
Net cash / market cap	3.65%
Net cash growth	-5.42%
Net debt / EBITDA	-1.7
Net debt / equity	-0.23
Net debt / FCF	-1.72
Piotroski F-Score	5
Property, plant and equipment	$9.8M
Shareholders' equity	$967.5M
Tangible book value	$656.7M
Tangible book value per share	$32.97
Total assets	$2.2B
Total cash	$1.4B
Total debt	$1.1B
Total liabilities	$1.2B
WACC	8.35%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.19
Current assets	$1.5B
Current liabilities	$46.7M
Current ratio	31.18
Inventory turnover	4.24
Net working capital	$53.7M
Quick ratio	30.83
Working capital	$1.4B
Working capital turnover	0.34

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-12.96%
Dividend per share	$0.00
Dividend yield	0%
Last dividend	$15.00
Shareholder yield	-12.96%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	238.7%
10Y return CAGR	18.04%
10Y total return	424.88%
150-day SMA	$269.25
15Y price change	1,962.23%
15Y return CAGR	25.98%
15Y total return	3,095.85%
1D price change	1.95%
1M price change	4.85%
1M total return	4.85%
1W price change	3.18%
1W total return	3.18%
1Y price change	66.42%
1Y return CAGR	66.47%
1Y total return	66.42%
20-day SMA	$303.46
200-day SMA	$251.37
20Y price change	383.37%
20Y return CAGR	12.2%
20Y total return	899.12%
3M price change	6.27%
3M total return	6.27%
3Y price change	537.77%
3Y return CAGR	85.42%
3Y total return	537.77%
50-day SMA	$295.10
50-day SMA vs 200-day SMA	50over200
52-week high	$326.63
52-week high date	2026-07-08
52-week low	$175.89
52-week low date	2026-01-13
5Y price change	127.1%
5Y return CAGR	28.62%
5Y total return	251.93%
6M price change	30.75%
6M total return	30.75%
All-time high	$326.63
All-time high date	2026-07-08
All-time low	$6.60
All-time low date	2008-10-28
Average true range (ATR)	$10.04
Average volume	222.9K
Beta (1Y)	0.69
Beta (2Y)	0.94
Beta (5Y)	1.01
Change from 52-week high	-2.7%
Change from 52-week low	80.69%
Change from all-time high	-3.21%
Change from all-time low	4,690%
Change from open	2.16%
Day's gap	-0.21%
Dollar volume	$70.8M
High price	$317.81
Low price	$311.09
Monthly RSI	78.04
Open price	$311.09
Position in 52-week range	100%
Premarket change	-0.72%
Premarket close	$311.73
Premarket price	$309.50
Premarket volume	304
Previous close	$311.73
Price vs 150-day SMA	17.41%
Price vs 20-day SMA	4.18%
Price vs 200-day SMA	25.77%
Price vs 50-day SMA	7.13%
Relative volume	1
RSI	60.21
Sharpe ratio	1.46
Sharpe ratio (3Y)	1.64
Sharpe ratio (5Y)	0.73
Sortino ratio	2.43
Sortino ratio (3Y)	2.76
Sortino ratio (5Y)	1.26
Volume	222.6K
Weekly RSI	70.27
YTD price change	67.21%
YTD total return	67.21%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	19.5M
Float percentage	97.76%
Shares change (QoQ)	9.83%
Shares change (YoY)	12.96%
Shares held by insiders	2.21%
Shares held by institutions	115.81%
Shares outstanding	19.9M
Short % of float	13.74%
Short % of shares	13.43%
Short ratio	10.6 days

Deeper analysis on LGND

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this LGND report

Is a complete LGND research report available?

No complete published report is available for Ligand Pharmaceuticals Incorporated (LGND) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Ligand Pharmaceuticals Incorporated (LGND)

Price

Financial snapshot

Fair-value bridge

Latest news · LGND

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All LGND indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on LGND

Frequently asked questions